Anzeige
Mehr »
Login
Samstag, 11.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Innocan Pharma News: Unfassbare Studie - LPT-Therapie bewahrt Patient vor dem Tod!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QMUH | ISIN: US92790C1045 | Ticker-Symbol: 1S1
Frankfurt
10.05.24
08:00 Uhr
12,500 Euro
-1,200
-8,76 %
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
VIRIDIAN THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
VIRIDIAN THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
12,70013,20010.05.
12,60013,30010.05.

Aktuelle News zur VIRIDIAN THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoEarnings call: Viridian Therapeutics reports robust progress in Q1 20241
DoViridian Therapeutics, Inc. (VRDN) Q1 2024 Earnings Call Transcript1
MiViridian Therapeutics, Inc.\DE - 10-Q, Quarterly Report1
MiViridian Therapeutics GAAP EPS of -$0.79 beats by $0.28, revenue of $0.07M misses by $0.01M1
MiViridian Therapeutics, Inc.\DE - 8-K, Current Report1
MiViridian Therapeutics Highlights Recent Progress and Reports First Quarter 2024 Financial Results53WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare...
► Artikel lesen
16.04.Viridian Therapeutics, Inc.\DE - 8-K, Current Report3
20.03.Unveiling 4 Analyst Insights On Viridian Therapeutics6
28.02.Viridian Therapeutics, Inc.\DE - S-8, Securities to be offered to employees in employee benefit plans1
28.02.Viridian Therapeutics GAAP EPS of -$1.353
27.02.Viridian Therapeutics, Inc.\DE - 10-K, Annual Report1
27.02.Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results102WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare...
► Artikel lesen
16.02.Viridian Therapeutics names new Chief Legal Officer1
19.01.Viridian Therapeutics, Inc.\DE - 8-K, Current Report2
18.01.Here's Why Viridian Therapeutics (VRDN) Stock Is Moving1
18.01.Viridian Therapeutics falls on $150 million equity offering1
18.01.Viridian Therapeutics stock slides on pricing stock offering to raise $150 million2
18.01.Viridian Therapeutics Prices Public Offering Of About 7.14 Mln Shares At $21.00/shr1
17.01.Viridian Therapeutics starts public offering of common and preferred stock1
08.01.Viridian Therapeutics, Inc.\DE - 8-K, Current Report1
Seite:  Weiter >>
30 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1